EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The safety profile of belzutifan in renal tumors: real-world data from a tertiary academic center

Aaron Jacob Winer iD, Paulo Siqueira do Amaral iD, Elizabeth G Ryan, Morgan A Lambrecht, Chiu-Lan Chen, Brian I Rini iD, Kathryn E Beckermann iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Aaron Jacob Winer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell, von Hippel-Lindau Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials; however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.

Methods

A retrospective analysis was conducted at Vanderbilt University Medical Center assessing patients who received belzutifan monotherapy. Primary endpoints were the incidence of anemia and hypoxia. Secondary endpoints included time to onset of anemia and hypoxia, as well as management strategies.

Results

Forty-four patients were identified with either spRCC (n = 22) or VHL syndrome (n = 22). Patients with spRCC were older than VHL patients (median 67 vs 41 years) and had higher rates of chronic kidney disease (36.4% vs 4.5%) and prior nephrectomy (77.3% vs 40.9%). The spRCC patients had a median follow-up time of 3.8 months vs 26.8 months in VHL patients. Any-grade anemia occurred in the majority of spRCC and VHL patients (81% and 95.5%, respectively) with a median time of 25 days in spRCC patients and 77 days in VHL patients. While no patient with VHL experienced grade 3 anemia, 41% of spRCC patients developed grade ≥3 anemia. In spRCC, grade ≥3 hypoxia developed in 54.5% and for VHL patients, grade 3 hypoxia occurred in 9%. Median time to grade ≥3 hypoxia was 29 days (range 12-123) in spRCC patients and 225 days (range 105-345) in VHL patients. Supplemental oxygen was required in 52.5% of spRCC patients and 9.5% in VHL patients. Treatment discontinuation due to AEs occurred in 50% of spRCC patients and 13.6% of VHL patients.

Conclusions

The time to onset and severity of belzutifan AEs may differ between patients with VHL syndrome and spRCC. These findings suggest the need for a patient-centered approach to monitor and manage toxicity based on disease setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsCarcinoma, Renal Cellvon Hippel-Lindau DiseaseHumansMaleFemaleAgedMiddle AgedAdultRetrospective StudiesTertiary Care CentersAnemiaIndenes

Stichwörter der Autor:innen

VHLanemiabelzutifanhypoxiasafetyspRCC

Substanzen

belzutifanIndenes

Autor:innen und Institutionen

  • Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
  • Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
  • Department of Biostatics, Vanderbilt University Medical Center, Nashville, TN 37232, United States.

ORCID-Profile: Aaron Jacob Winer, Paulo Siqueira do Amaral, Brian I Rini, Kathryn E Beckermann

Zitieren

APA

Winer, A. J., do Amaral, P. S., Ryan, E. G., Lambrecht, M. A., Chen, C. L., Rini, B. I., & Beckermann, K. E. (2025). The safety profile of belzutifan in renal tumors: real-world data from a tertiary academic center. The Oncologist. https://doi.org/10.1093/oncolo/oyaf274

Vancouver

Winer AJ, do Amaral PS, Ryan EG, Lambrecht MA, Chen CL, Rini BI, et al. The safety profile of belzutifan in renal tumors: real-world data from a tertiary academic center. The Oncologist. 2025. doi:10.1093/oncolo/oyaf274

BibTeX
@article{Winer2025,
  author = {Winer, Aaron Jacob and do Amaral, Paulo Siqueira and Ryan, Elizabeth G and Lambrecht, Morgan A and Chen, Chiu-Lan and Rini, Brian I and Beckermann, Kathryn E},
  title = {The safety profile of belzutifan in renal tumors: real-world data from a tertiary academic center},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf274}
}
Kostenlos starten →